Aleksandra Sojda

Dr. Aleksandra Sojda

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2025 in Archives of Medical Science
Verified
Journal Article
Open access
Artur DziewierzArtur Dziewierz
Artur Dziewierz
RRRenata Rajtar-Salwa
Renata Rajtar-Salwa
Lukasz SzarpakLukasz Szarpak
Lukasz Szarpak
ASAleksandra Sojda
Aleksandra Sojda
Zbigniew SiudakZbigniew Siudak
Zbigniew Siudak
We conducted a descriptive, retrospective analysis of electronic medical records from LUX MED [7, 8], a major private healthcare provider in Poland, spanning January 1, 2018, to December 31, 2024. We included all new adult patients (≥ 18 years) with a recorded BMI ≥ 27 kg/m2 and no diagnosis of type 1 or type 2 diabetes mellitus. Eligibility for GLP-1 RA therapy for weight management was defined as: (1) BMI ≥ 30 kg/m2, or (2) BMI 27–29.9 kg/m2 with at least one documented weight-related comorbidity (arterial hypertension, coronary artery disease, hypercholesterolemia, or sleep apnea). We extracted baseline demographic and clinical characteristics. Analyses were restricted to ‘new patients’, defined as individuals with their first recorded Luxmed encounter during the study period. This criterion ensured consistent capture of baseline BMI, comorbidity, and prescription data from the start of each patient’s record and reduced misclassification of prior GLP-1 RA exposure. The primary outcome was GLP-1 RA initiation (semaglutide (oral or subcutaneous) or tirzepatide) following eligibility determination. GLP-1 RA initiation was defined as the first-ever recorded prescription of any GLP-1 RA agent in the Luxmed database during the study period. Each patient was counted only once, at the date of their first prescription; subsequent prescriptions were not considered additional initiations. Annual initiation prevalence was calculated for each eligible BMI subgroup.

12 November 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
KNKlaudia Nowak
Klaudia Nowak
Artur DziewierzArtur Dziewierz
Artur Dziewierz
ASAleksandra Sojda
Aleksandra Sojda
MZMichał Zabojszcz
Michał Zabojszcz
Lukasz SzarpakLukasz Szarpak
Lukasz Szarpak
Zbigniew SiudakZbigniew Siudak
Zbigniew Siudak
Background: Since the introduction of the first GLP-1 receptor agonist (GLP-1 RA) in 2005, there has been a steady increase in the number of drugs available in this group, as well as an expansion of their indications and routes of administration. Aim: The aim of the study was to assess the clinical characteristics of patients treated with GLP-1 RA in Poland in 2018–2024, with particular emphasis on the disease entities constituting indications for treatment (like obesity and diabetes), and to analyse the frequency of use of individual drugs during the study period. Methods: A cohort study was conducted based on anonymised medical data from 300 outpatient clinics the largest private healthcare facilities in Poland (Luxmed), on consecutive patients who had at least one prescription for GLP-1 RA. The analysis covered the period from 1 January 2018 to 31 December 2024. Results: The number of patients using GLP-1 RA increased from 212 in 2018 to 12,836 in 2024. Obesity was diagnosed in 78% of all patients, most often in the groups using liraglutide and tirzepatide. The highest percentage of patients with type 2 diabetes was observed in the dulaglutide group (67%), while the lowest was in the tirzepatide group (15%). From 2022, the share of oral semaglutide steadily increased, reaching 50% of all semaglutide applications in 2024 in Poland. Conclusions: In the analysed group, GLP-1 RAs were most commonly used to treat obesity. The oral form of semaglutide was more frequently used in younger females with less aggravating medical history.

24 May 2026 in American Journal of Case Reports
Verified
Journal Article
Open access
MKMateusz P. Kubicki
Mateusz P. Kubicki
PKPatrycja Krawczyk
Patrycja Krawczyk
EOEmil ObręBski
Emil ObręBski
ASAleksandra Sojda
Aleksandra Sojda
WSWeronika StęPień
Weronika StęPień
LNLukasz Nawacki
Lukasz Nawacki
A Patient With a Left Ventricular Assist Device Requiring Emergency Surgery for a Strangulated Umbilical Hernia: A Case Report - Article abstract #951673

1 June 2026 in Updates in Surgery
Verified
Journal Article
Open access
EOEmil ObręBski
Emil ObręBski
MCMaja Chowańska
Maja Chowańska
JKJakub Kozłowski
Jakub Kozłowski
DGDamian GręBosz
Damian GręBosz
WPWeronika Płachta
Weronika Płachta
BMBartosz Molasy
Bartosz Molasy
Emergency inguinal hernia repair is associated with increased perioperative risk, but its effect on longer-term outcomes remains unclear. Adult patients undergoing inguinal hernia repair between 2022 and 2024 were analyzed, comparing emergency and elective procedures. Demographic and perioperative data were obtained from medical records. Recurrence and chronic pain (≥ 6 months) were assessed prospectively using structured telephone follow-up at 12–18 months. Among 400 patients, 26 (6.5%) underwent emergency repair and 374 (93.5%) elective repair; follow-up was available for 292 patients (73%). Emergency patients were older (median 73.0 vs. 64.0 years; p = 0.011), had longer operative time (80.0 vs. 65.0 min; p < 0.001), and longer hospital stay (2.0 vs. 1.0 days; p < 0.001). Surgical site infection within 90 days occurred more frequently after emergency repair (7.7% vs. 1.3%; OR 5.93, 95% CI 1.08–32.74; p = 0.041), with similar results in open repairs only. Recurrence (3.8% vs. 3.5%) and chronic pain (11.5% vs. 13.4%) did not differ between emergency and elective repairs (both p > 0.05). Emergency inguinal hernia repair is associated with higher early postoperative morbidity, while recurrence and chronic pain rates during mid-term follow-up are comparable to elective surgery.